GoodRx Holdings, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
GoodRx Holdings, Inc. (GDRX) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$25.25 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2022-03-01
- GoodRx Holdings, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-12-31 was -$39.91M.
- GoodRx Holdings, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-09-30 was -$18.07M.
- GoodRx Holdings, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-06-30 was $31.06M, a 74.09% increase year-over-year.
- GoodRx Holdings, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-03-31 was $1.67M, a 90.65% decline year-over-year.
- GoodRx Holdings, Inc. net income (loss) available to common stockholders, diluted for fiscal 2021 was -$25.25M.
- GoodRx Holdings, Inc. net income (loss) available to common stockholders, diluted for fiscal 2020 was -$293.62M, a 786.92% decline from fiscal 2019.
- GoodRx Holdings, Inc. net income (loss) available to common stockholders, diluted for fiscal 2019 was $42.74M, a 200.47% increase from fiscal 2018.
- GoodRx Holdings, Inc. net income (loss) available to common stockholders, diluted for fiscal 2018 was $14.23M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$39.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$57.98M derived: sum of 2 quarters · filed 2022-03-01 | -$26.92M derived: sum of 3 quarters · filed 2022-03-01 | -$25.25M 10-K · filed 2022-03-01 |
| 2021-09-30 | -$18.07M 10-Q · filed 2021-11-12 | $12.99M derived: sum of 2 quarters · filed 2021-11-12 | $14.66M 10-Q · filed 2021-11-12 | -$282.06M derived: sum of 4 quarters · filed 2022-03-01 |
| 2021-06-30 | $31.06M 10-Q · filed 2021-08-12 | $32.73M 10-Q · filed 2021-08-12 | -$263.99M derived: sum of 3 quarters · filed 2022-03-01 | -$314.02M derived: sum of 4 quarters · filed 2022-03-01 |
| 2021-03-31 | $1.67M 10-Q · filed 2021-05-14 | -$295.05M derived: sum of 2 quarters · filed 2022-03-01 | -$345.08M derived: sum of 3 quarters · filed 2022-03-01 | -$327.24M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-12-31 | -$296.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$346.75M derived: sum of 2 quarters · filed 2022-03-01 | -$328.90M derived: sum of 3 quarters · filed 2022-03-01 | -$293.62M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$50.03M 10-Q · filed 2021-11-12 | -$32.19M derived: sum of 2 quarters · filed 2021-11-12 | $3.09M 10-Q · filed 2021-11-12 | -$4.47M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $17.84M 10-Q · filed 2021-08-12 | $35.67M 10-Q · filed 2021-08-12 | $45.56M derived: sum of 3 quarters · filed 2022-03-01 | $58.27M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $17.83M 10-Q · filed 2021-05-14 | $27.72M derived: sum of 2 quarters · filed 2022-03-01 | $40.43M derived: sum of 3 quarters · filed 2022-03-01 | |
| 2019-12-31 | $9.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $22.59M derived: sum of 2 quarters · filed 2022-03-01 | $42.74M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $12.71M 10-Q · filed 2020-11-12 | $32.86M 10-Q · filed 2020-11-12 | ||
| 2018-12-31 | $14.23M 10-K · filed 2021-03-12 |